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Abstract Angiogenesis, or the formation of new mi-
crovasculature, is a physiological process that may occur in
the setting of chronic tissue ischemia and can play an im-
portant role in improving tissue perfusion and blood flow
following myocardial infarction or in the presence of pe-
ripheral vascular disease (PVD). Molecular imaging of
angiogenesis within the cardiovascular system is a devel-
oping field of study. Targeted imaging of angiogenesis has
the potential for non-invasive assessment of the underlying
molecular signaling events associated with the angiogenic
process and, when applied in conjunction with physio-
logical perfusion imaging, may be utilized to predict and
evaluate clinical outcomes in the setting of ischemic heart
disease or PVD. This review discusses the developing ra-
diotracer-based imaging techniques and technology cur-
rently in use that possess potential for clinical translation,
with specific focus on PET and SPECT imaging of my-
ocardial and peripheral angiogenesis.
Keywords Myocardial angiogenesis  Peripheral
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Introduction
Molecular imaging is a technique that is focused on the
non-invasive assessment of in vivo molecular and associ-
ated physiological processes. The most established mod-
alities used for molecular imaging are single photon
emission computed tomography (SPECT) and positron
emission tomography (PET), which use radiotracers that
are capable of targeting specific biological events associ-
ated with disease progression and therapeutic success. Both
SPECT and PET possess high sensitivity and good tissue
penetration depth, making them ideal modalities for tar-
geted molecular imaging. The development of hybrid
imaging systems in recent years now permits co-localiza-
tion of high-sensitivity functional SPECT and PET images
with high-spatial resolution anatomical images from X-ray
computed tomography (CT) and magnetic resonance (MR)
systems. These hybrid systems allow for attenuation cor-
rection and partial volume correction, thereby improving
localization and quantification of radiotracer uptake within
specific anatomical regions of interest (e.g., organ systems,
soft tissue, vascular networks) [1].
The most established modality for molecular imaging is
PET; however, SPECT imaging offers some advantages.
SPECT cameras are less expensive and more widely
available compared to PET systems. SPECT systems allow
for the routine use of dual radioisotope imaging through the
differentiation of gamma emitters, thus permitting simul-
taneous imaging of molecular and physiological indices,
such as angiogenesis and tissue perfusion. The use of PET
systems continues to grow due to increased availability of
hybrid systems with higher sensitivity for detection of
molecular events and higher spatial resolution imaging
than traditional SPECT systems. Additionally, PET imag-
ing commonly incorporates radiotracers with shorter half-
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lives, which ultimately results in decreased patient expo-
sure to ionizing radiation [2]. Recent pre-clinical work
suggests the possibility of dual-isotope PET imaging using
pure positron emitters (e.g., nitrogen-13, fluorine-18) and
radiotracers that emit a prompt gamma (e.g., rubidium-82,
bromine-76, iodine-124) in association with the primary
beta, allowing newer PET systems with faster electronics
and shorter detector decay constants the ability to detect
coincidences and triplets [3, 4].
One physiological process of significant interest in the
medical community that may be better evaluated through
the use of radiotracer-based molecular imaging is angio-
genesis, a process that plays an important role in the
restoration of tissue perfusion and blood flow following the
onset of myocardial and skeletal muscle ischemia [5].
Traditional assessment of angiogenesis has been restricted
to postmortem histological analyses that require the killing
of large numbers of animals to validate quantitative find-
ings, thus increasing research costs and decreasing clinical
relevance of therapies targeted at promoting or hindering
the process of angiogenesis. Further development of
molecular imaging approaches should facilitate the trans-
lation of novel therapeutics into clinical trials and improve
patient management by permitting non-invasive assessment
of serial angiogenic responses to treatment.
Angiogenesis
Angiogenesis, in general, is the physiological process by
which new capillaries are formed from pre-existing vessels.
Formation of new microvascular networks can be of cri-
tical significance in the setting of cardiovascular disease, as
angiogenesis can assist in restoring blood flow and perfu-
sion to skeletal muscle or cardiac tissue exposed to hypoxic
conditions and potentially prevent the onset of tissue
necrosis. Angiogenesis is regulated through multiple an-
giogenic factors, cells, and the extracellular matrix (ECM),
and can be stimulated in the setting of various conditions
that may be associated with cardiovascular disease, such as
ischemia, hypoxia, inflammation, and alterations in vas-
cular shear stress [5]. The process of angiogenesis can be
described by several stages. These stages are first charac-
terized by the initial activation of endothelial cells that
leads to increased permeability and proliferation of en-
dothelial cells. Next, the extracellular matrix (ECM) is
degraded, with the assistance of multiple factors such as
matrix metalloproteinases (MMPs) and integrins, which
facilitates infiltration of endothelial cells. Following ECM
breakdown and endothelial cell migration, the development
and eventual stabilization of a new capillary occurs [6].
Numerous factors have been attributed to stimulating
angiogenesis in the setting of tissue hypoxia, such as
hypoxia-inducible factor 1 (HIF-1), vascular endothelial
growth factor (VEGF), platelet-derived growth factor
(PDGF), fibroblast growth factor-2 (FGF-2), transforming
growth factor beta (TGF-b), and angiopoietins [7–10].
With the assistance of the aforementioned angiogenic
mediators, additional signaling events result in participa-
tion of endothelial cells, vascular smooth muscle cells,
blood-derived macrophages, and circulating stem cells in
the angiogenic process [11]. In addition to macrophages, a
variety of other inflammatory cells and mediators can play
important roles in angiogenesis. Through hypoxia-induced
stimulation, inflammatory cells can release multiple an-
giogenesis-stimulating factors and proteases, such as vas-
cular endothelial growth factor (VEGF), tumor necrosis
factor-a (TNF-a), cytokines, and MMPs. Inflammatory
cells can also release reactive oxygen species (ROS), which
can serve as stimulators of the angiogenic process [6].
While there are many known mediators of the angio-
genic process, VEGF has been established as one of the
most influential contributors to vascular development. Five
VEGF-related growth factors exist, which stimulate an-
giogenesis through binding to three tyrosine kinase recep-
tors (VEGFR-1, VEGR-2, and VEGR-3) [12]. Along with
VEGF’s established role, integrins are also considered to
be important regulators of the angiogenic process. These
transmembrane receptors are capable of mediating cell-to-
cell and cell-to-ECM interactions and can modulate cell
adhesion, migration, proliferation, differentiation, and
survival. The avb3 integrin has been of particular interest
due to significant involvement in the regulation of cell
interactions with the ECM and endothelial cell migration
[13]. As the field of molecular imaging continues to de-
velop, VEGF and the avb3 integrin have emerged as the
primary targets for non-invasive evaluation of cardiovas-
cular-related angiogenesis; however, multiple targets are
currently available for the evaluation of angiogenesis in the
setting of cancer, cardiovascular disease, and inflammation.
Established targets for molecular imaging of angiogenesis
have been grouped into three categories: 1) non-endothelial
cell targets (e.g., monocytes, macrophages, and stem cells),
endothelial cell targets (e.g., VEGF, receptors, and inte-
grins), and 3) ECM proteins and proteases [5]. Future
discussion will be limited to translational cardiovascular
imaging approaches that have been performed for the non-
invasive assessment of myocardial and peripheral
angiogenesis.
Radiotracer imaging of myocardial angiogenesis
Angiogenesis is enhanced in the setting of myocardial is-
chemia as a physiological response to ischemic insult,
particularly in the setting of myocardial infarction (MI). In
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animal models of MI, angiogenic activation after MI can be
confirmed by histopathologic analysis, such as capillary
density measurement. However, non-invasive imaging is
currently the only practical method for evaluating angio-
genesis in vivo. Many studies have reported augmented
angiogenesis following MI as well as cerebral infarction by
using radiotracer imaging methods [14, 15]. Among ra-
diotracer-based studies targeted at the angiogenic process,
the RGD peptide (composed of L-arginine, glycine, and L-
aspartic acid) moiety targeted at the integrin avb3 has been
most widely applied. The avb3 integrin is expressed on the
surface of the endothelium that is activated for angio-
genesis. Additionally, the expression of avb3 integrin is
present on activated macrophages. Thus, the RGD peptide
moiety targets for both post-infarct angiogenesis and
macrophage accumulation. The uptake of RGD peptide
agents in the post-infarct myocardium has been demon-
strated to be closely related to expression of CD31 (an-
giogenesis marker) and CD68 (macrophage marker), as
well as integrin expression [16–20].
Many studies have reported visualization and quantifi-
cation of increased angiogenesis following MI using ra-
diotracer-based imaging approaches. Early application of
radiotracer-based imaging for the evaluation of post-MI
angiogenesis was performed using scintigraphy or single
photon emission computed tomography (SPECT). SPECT
imaging with indium-111 (111In)-RP748 in rat and canine
models of MI have demonstrated a 2- to 4-fold increase in
myocardial uptake within infarcted myocardium compared
to remote regions [16, 21, 22]. Technetium-99 m (99mTc) is
currently a more readily accessible radioisotope than 111In,
and studies using 99mTc-labeled RGD peptides (99mTc-
RAFT-RGD and 99mTc-NC100692) have shown increased
accumulation of these radiotracers within infarcted my-
ocardium and the border zone of infarction (Fig. 1) [17,
23]. PET imaging has become more widely available for
pre-clinical and clinical imaging, and angiogenesis-target-
ed radiotracers for PET have been investigated more ex-
tensively than radiotracers for gamma cameras. Flourine-
18 (18F)-galacto-RGD [24, 25], copper-64 (64Cu)-VEGF
[26], 18F-PRGD [18], 64Cu-TRC105 [27], and several
gallium-68 (68Ga)-labeled RGD peptide agents [19, 20, 28,
29] have been reported to be effective for PET imaging of
post-infarct angiogenesis (Table 1). Pre-clinical PET
studies in animal models of MI have demonstrated a 1.5- to
3.9-fold increase in angiogenesis activity from baseline
levels within infarcted myocardium [18–20, 27]. In addi-
tion to pre-clinical application, some PET angiogenesis-
targeted tracers have reached the clinical setting for the
assessment of post-MI remodeling and have demonstrated
approximately a 2-fold increase in radiotracer uptake
within infarcted myocardium when compared to normal or
remote myocardium [25, 28].
The natural time course of post-infarct remodeling can
be serially evaluated using non-invasive angiogenesis-tar-
geted imaging. Despite differences that exist in the animal
models studied and the radiotracers incorporated, increased
angiogenesis (as assessed by avb3 integrin activation) has
commonly been observed within 1–3 days after occurrence
of MI [16, 22, 24, 25]. In the majority of studies, my-
ocardial uptake of radiotracers reached peak levels at
1–3 weeks following infarction [18, 23, 24, 28]. However,
considerable variation in the persistence of angiogenesis
signal has been demonstrated, with some studies reporting
that radiotracer uptake is normalized as early as 17 days
following infarction [27], whereas other studies report
Fig. 1 SPECT imaging of
myocardial angiogenesis in a
canine model of myocardial
infarction obtained 2 weeks
following 6 h balloon occlusion
of the left anterior descending
artery. Focal uptake of 99mTc-
NC100692 is observed in the
region of myocardial infarction
(denoted by white arrow),
which is localized to a region of
decreased perfusion, as
identified by 201Tl SPECT
(yellow arrow) (color figure
online)
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persistent uptake for up to 4–6 months [18, 24]. Work in
our own laboratory has demonstrated normalization of the
angiogenic response at approximately 6–9 weeks following
MI in a canine model of temporary left anterior descending
artery (LAD) occlusion [23]. The differences in the time
courses for angiogenesis that have been observed following
MI may be related to a number of variables, including the
animal model being utilized and the duration and site of
coronary occlusion.
In recent years, therapeutic angiogenesis using various
growth factors and gene- or cell-based therapies have been
attempted to induce angiogenesis and relieve myocardial
ischemia. Pre-clinical application of SPECT and PET
imaging has demonstrated that radiotracer-based imaging
of angiogenesis may be useful for monitoring the effect of
therapeutic treatments. In a swine model of hibernating
myocardium, focal uptake of iodine-123 (123I)-gluco-RGD
was found to correspond with sites of prior intra-myocar-
dial VEFG injections and correlated with postmortem
analysis of capillary density [30]. In addition to the use of
123I-gluco-RGD for monitoring of VEGF therapy in in-
farcted myocardium, 99mTc-RAFT-RGD SPECT and 68Ga-
NOTA-RGD PET imaging have also been used to evaluate
VEGF and fibroblast growth factor therapies in rat models
of MI [19, 30]. In these studies, radiotracer uptake was
observed in accordance with increased capillary density
and other markers of angiogenesis. Other pre-clinical work
using micro-SPECT/CT imaging of 99mTc-NC100692 has
demonstrated potential for evaluating the angiogenic re-
sponse to insulin-like growth factor-1 gene therapy in a rat
model of MI, suggesting that monitoring of therapeutic
efficacy with angiogenesis imaging could have potential
for clinical application [31].
Molecular imaging of myocardial angiogenesis has been
translated to the clinical setting for the evaluation of pa-
tients with hypertrophic cardiomyopathy [32] and heart
failure [33], as well as following acute MI [25]. In the
evaluation of acute MI, focal uptake of 18F-galacto-RGD
has been shown to localize to the MI area defined by de-
layed enhancement magnetic resonance (MR) imaging
[25]. The use of 99mTc-NC100692 in patients with hyper-
trophic cardiomyopathy has also demonstrated higher-
grade radiotracer uptake within regions of fibrosis detected
by MR [32]. Additionally, 99mTc-NC100692 has been used
to evaluate the therapeutic efficacy of bone marrow-
derived stem cell therapy in patients with heart failure;
however, radiotracer uptake was found to be only mildly
correlated with functional improvement [33]. Further in-
vestigation into the long-term prognostic role of monitor-
ing the angiogenesis process in the setting of hypertrophic
heart disease, following MI, or in the evaluation of
therapeutic treatments is warranted, while the context of
clinical conditions should also be considered in the inter-
pretation of molecular imaging strategies.
Radiotracer imaging of peripheral angiogenesis
In addition to being a useful tool for non-invasive assess-
ment of myocardial ischemia, molecular imaging of an-
giogenesis has also proven to be effective in the evaluation
of limb ischemia. Ischemia-induced angiogenesis has been
demonstrated to occur in various pre-clinical models of
femoral artery occlusion, such as rodent [34–36], rabbit
[37], and pig models [38]. Although molecular imaging of
peripheral angiogenesis has not yet reached clinical ap-
plication, pre-clinical work has shown promising results for
non-invasive serial analysis of the angiogenic process, with
the primary vascular targets of choice being VEGF re-
ceptors and the avb3 integrin.
In one of the first molecular imaging studies targeting
peripheral angiogenesis, Lu et al. [37] targeted VEGF re-
ceptors in a rabbit model of unilateral hind limb ischemia
using planar imaging and gamma counting of 111In-labeled
recombinant human VEGF121. Ten days following surgi-
cally induced limb ischemia, both imaging and gamma
counting demonstrated increased uptake of 111In-labeled
Table 1 Radiotracers for imaging of cardiovascular angiogenesis
Biologic target Radiotracer Modality
Myocardial
Pre-clinical 64Cu-DOTA-VEGF121 [26] PET
64Cu-NOTA-TRC105 [27] PET
18F-Galacto-RGD [24, 29] PET






99mTc-NC100692 [31, 44, 45] SPECT
99mTc-RAFT-RGD [17] SPECT
111In-RP748 [16, 21, 22] SPECT







64Cu-NOTA-TRC105 [34, 46] PET
99mTc-NC100692 [36, 40, 47, 48] SPECT
111In-VEGF121 [37] SPECT
125I-c(RGD(I)yV) [39] SPECT
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VEGF121 in ischemic vs. control hind limb tissue. Fur-
thermore, immunohistochemical analysis of ischemic tis-
sue confirmed an increase in VEGF receptor expression.
Along with targeting of VEGF receptors, early work in
mouse models of hind limb ischemia also targeted the avb3
integrin using iodine-125 (125I)- and 99mTc-labeled RGD
peptides [39, 40]. Lee et al. [39] evaluated 125I-
c(RGD(I)yV uptake in ischemic hind limb tissue using
gamma counting and found significantly increased radio-
tracer uptake at days 3, 8, and 14 following femoral abla-
tion, which was also associated with gradual recovery of
limb perfusion (evaluated by laser Doppler). Additionally,
radiotracer uptake was validated through immunohisto-
chemistry that demonstrated a pronounced increase in
avb3 integrin expression in ischemic tissue. Further
evaluation of serial changes in avb3 integrin expression
during the angiogenic process has been performed in the
ischemic hind limb through non-invasive in vivo planar
imaging of 99mTc-NC100692 [40]. Imaging demonstrated
radiotracer uptake in the distal hind limb that increased at
3 days and peaked at 7 days following femoral artery oc-
clusion. Image quantification was validated by gamma
counting of hind limb tissue, and increased radiotracer
uptake corresponded with serial increases in capillary
density. Additionally, immunofluorescent staining con-
firmed specificity and co-localization of NC100692 (tar-
geting the avb3 integrin) to endothelial cells. Further work
has validated and applied a semiautomated quantitative
approach for serial micro-SPECT/CT imaging of 99mTc-
NC100692 and demonstrated high reproducibility and ac-
curacy of this approach for evaluating angiogenesis within
specific volumes of interest in the hind limbs of wild-type
and endothelial nitric oxide synthase (eNOS) knockout
mice [36]. Peak 99mTc-NC100692 uptake was found to
occur 1 week following femoral artery occlusion in both
wild-type and eNOS knockout mice; however, there was a
significant decrease in radiotracer uptake in eNOS-defi-
cient mice relative to wild-type mice at the 1 week post-
occlusion time point. These results suggest that SPECT/CT
imaging of angiogenesis may be a useful non-invasive tool
for future translational studies evaluating different stages
and forms of disease, such as peripheral vascular disease
and diabetes. Work from our laboratory has recently fo-
cused on translating 99mTc-NC100692 SPECT/CT imaging
from a small to large animal model of hind limb ischemia
to non-invasively evaluate serial changes in angiogenesis
and has demonstrated focal radiotracer uptake within is-
chemic tissue and surgical site (Fig. 2).
In addition to 111In and 99mTc labeling of angiogenesis-
targeted compounds, 68Ga [41] and 64Cu [42] have also
been used for non-invasive assessment of angiogenesis in
the mouse model of hind limb ischemia. In a feasibility
study by Jeong et al. [41], 68Ga-NOTA-RGD targeted at
the avb3 integrin demonstrated specific uptake by angio-
genic hind limb tissue, high stability, high affinity for the
avb3 integrin, and good pharmacokinetic properties. In
another study utilizing micro-PET imaging of 64Cu-
VEGF121, radiotracer uptake was significantly increased in
ischemic hind limb tissue 8 days following femoral artery
ligation and subsequently displayed a steady decrease in
uptake over the following 3 weeks [42]. Interestingly,
64Cu-VEGF121 uptake was also significantly higher in the
skeletal muscle of mice exposed to hind limb ischemia and
exercise training when compared to non-exercised controls,
with radiotracer uptake being strongly correlated with
VEGFR2 tissue levels.
64Cu has also been used for labeling of C-type atrial
natriuretic factor (CANF)-conjugated comblike nanoprobes
for detecting the upregulation of natriuretic peptide clear-
ance receptor (NPR-C) in the setting of hind limb ischemia
[43]. PET imaging of targeted 64Cu-DOTA-CANF-comb
demonstrated a nearly 6-fold increase in radiotracer uptake
at 24 h post-femoral artery ligation in the ischemic hind
limb relative to the non-ischemic control limb, which
corresponded with gradual recovery of blood flow,
indicative of a progressive angiogenic response. Immuno-
histochemistry established co-localization of NPR-C in
endothelial and smooth muscle cells, and specificity of
Fig. 2 Serial imaging of
angiogenesis in a pig model of
hind limb ischemia. Fused
99mTc-NC100692 SPECT and
CT axial images at 2 (a) and 4
(b) weeks post-femoral artery
occlusion demonstrate focal
uptake of 99mTc-NC100692 in
the lateral aspect of the hind
limb (white arrows), as well as
in the surgical site (yellow
arrows) (color figure online)
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64Cu-DOTA-CANF-comb to NPR-C was demonstrated via
competitive receptor blocking. In addition to 64Cu-labeled
nanoprobes, Almutairi et al. developed biodegradable
dendritic nanoprobes that were functionalized with heter-
obifunctional polyethylene oxide (PEO) chains and used
for targeted PET imaging of the avb3 integrin in hind limb
angiogenesis [35]. PEO chains were fitted with RGD mo-
tifs for selective targeting of the avb3 integrin. Labeling of
nanoprobes with 125I for cell-based assays demonstrated a
6-fold increase in nanoprobe uptake within avb3-positive
cells. Additionally, in vivo PET imaging of bromine-76
(76Br)-labeled nanoprobes confirmed specific uptake within
angiogenic hind limb tissue.
Most recently, 64Cu-labeleling of NOTA-conjugated
TRC105, a CD105 antibody, has been developed for PET
imaging of angiogenesis in the mouse model of hind limb
ischemia [27]. The first serial imaging study evaluating 64Cu-
TRC105 demonstrated peak radiotracer uptake at 3 and
10 days following femoral artery ligation, which was
validated using histology and reverse transcription poly-
merase chain reaction (RT-PCR) of hind limb tissue. Further
application of 64Cu-TRC105 has demonstrated the ability of
this radiotracer to non-invasively track serial changes in an-
giogenesis following pravastatin therapy in the setting of hind
limb ischemia and has showed significantly higher levels of
radiotracer uptake in treatment vs. non-treatment groups [34].
These findings suggest that non-invasive molecular imaging
of peripheral angiogenesis may have potential for evaluating
and monitoring serial responses to clinical treatment in pa-
tients with peripheral vascular disease.
Conclusions
Future translation of angiogenesis-targeted imaging with ra-
diotracer-based approaches may advance evaluation of my-
ocardial ischemia/infarction and peripheral vascular disease
in the clinical setting. Additionally, molecular imaging of
angiogenesis may allow for improved non-invasive assess-
ment of serial responses to medical treatment, including
revascularization, exercise training, and novel therapeutics.
Ongoing SPECT and PET imaging studies targeted at the
angiogenic process should focus on the development of ra-
diotracers that will result in reasonable levels of ionizing ra-
diation exposure for patients while also possessing high
affinity for angiogenesis-related vascular targets, thereby fa-
cilitating clinical translational of molecular imaging ap-
proaches that should allow for integration of physiologic
information with standard anatomic and clinical indices.
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